Starting a daily aspirin regimen in people age 60 or older can cause potentially serious harm including internal bleeding, the USPSTF warned Tuesday.

The portable sensor, developed by specialists at the University of Notre Dame and University of Florida, targets the patient's microRNA.

Patients given clopidogrel plus aspirin faced a lower risk of adverse events than those given ticagrelor plus aspirin.

The new study, published in the Journal of the American Heart Association, focused on nearly 290,000 NSTEMI patients.

The new method is expected to speed up image acquisition while providing clinicians with key data. 

The two-year analysis included patients with a confirmed diagnosis of coronary heart disease.